CDXS codexis.com: Business Value

codexis.com (CDXS) - corporate logo

This price action chart for Codexis, Inc. (CDXS) demonstrates an Enterprise Value of 159.61. The business relies on synthetic biology, generating excess profits from the licensing of proprietary enzymes. Its innovative development vector is based on CodeEvolver to accelerate chemical processes in medicine. Meanwhile, the operating environment is shielded from sanctions and trade conflicts, as development is conducted strictly within the US.

CDXS codexis.com: Enterprise Value in the range 11/23/2025 - 10/27/2026
Original product of Codexis

Enterprise Value represents the total buyout price of a business, summing market capitalization and debt minus cash. By analyzing the market value of the business adjusted for net debt, an investor assesses the real scale of Codexis, Inc. assets during the transition to a licensing model, which allows for a more accurate forecast of the impact of lower unit costs and increased operating leverage.

Direct competitors

TEM - Business Value|Qiagen Group (QGEN) - Real Price to Acquire Entire Company|IONS: Business Value|Repligen Corporation - Total Company Value|aviditybiosciences.com (RNA) - Company Buyout Price|Enterprise Value CRISPR Therapeutics (CRSP)|Business Value WGS|Total Company Value Ultragenyx Pharma RARE|Business Value Beam Tx (BEAM)|Enterprise Value SRPT (Sarepta Therapeutics, Inc.)|Enterprise Value twistbioscience.com TWST|TXG: Enterprise Value|NTLA: Real Price to Acquire Entire Company|Total Company Value STOK|BioLife (BLFS) - Total Enterprise Value|Enterprise Value Wave Life Sciences (WVE)|Business Value mazetx.com|Sionna Therapeutics - Enterprise Value|Total Enterprise Value Prime Medicine Inc PRME|TSHA - Real Price to Acquire Entire Company|Business Value uniQure Pharma QURE|Enterprise Value MGTX (MeiraGTx Holdings plc)|RGNX: Company Buyout Price|Solid Biosciences - Total Company Value|Company Buyout Price Ocugen Inc|PACB - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Benitec Corp|DSGN (Design Therapeutics) - Enterprise Value|Company Buyout Price RCKT (rocketpharma.com)|FDMT - Total Company Value|Business Value Lexeo Therapeutics Inc. LXEO|KRRO: Enterprise Value|Editas Corp (EDIT) - Real Price to Acquire Entire Company|Silence Therapeutics - Real Price to Acquire Entire Company|ProQR Therapeutics (PRQR) - Company Buyout Price|Enterprise Value SGMO|Real Price to Acquire Entire Company Nautilus Biotechnology Inc|Enterprise Value Metagenomi, Inc MGX|Business Value precisionbiosciences.com DTIL|GBIO - Real Price to Acquire Entire Company|boundlessbio.com - Business Value|Total Company Value XCUR (Exicure Corp)|IMNN - Company Buyout Price|Enterprise Value phiopharma.com|MBIO (Mustang Bio) - Business Value|Total Company Value TransCode Therapeutics Inc. (RNAZ)|Business Value Bionano|Enterprise Value APDN|Enterprise Value bluebird bio Inc. (BLUE)|ImmunoPrecise Antibodies Ltd. - Enterprise Value|Omega Therapeutics Corp - Real Price to Acquire Entire Company|OMIC (Singular Genomics Systems) - Total Company Value|RGLS - Total Enterprise Value|Enterprise Value Syros Pharmaceuticals, Inc.|Telesis Bio Inc. (TBIO) - Business Value|Enterprise Value TCON (TRACON)|Total Enterprise Value Unity Biotechnology, Inc (UBX)